Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: One case report from China

Hepato-Gastroenterology

Volumn 57, Issue 99-100, 2010, Pages 426-429

  Wang, Qun ^a   Yin, Tao ^a  

^a Hu Bei Cancer Hospital No116   (China)

Author keywords

Hepatic arterial infusion chemotherapy; Intrahepatic cholangiocarcinoma; Sorafenib

Indexed keywords

CAMPTOTHECIN; FLT3 LIGAND; FLUOROURACIL; FOLINIC ACID; HYDROXY CAMPTOTHECINE; OXALIPLATIN; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CASE REPORT; CHINA; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; IN VITRO STUDY; LIVER CIRCULATION; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES;

EID: 77955482988     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Blechacz B, Gores GJ: Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. Hepatology, 2008; 48:308-21
2. Khan SA, Thomas HC, Davidson BR, et al: Cholangiocarcinoma. Lancet, 2005; 366:1303-14
3. LaRocca RV, Hicks MD, Mull L, et al: Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. J Gastrointest Cancer, 2007; 38:154-6
4. Kudoh K, Doi K, Ohchi T, et al: [A case of intrahepatic cholangiocarcinoma successfully treated by hepatic arterial infusion chemotherapy]. Gan To Kagaku Ryoho , 2007;34:1993-5
5. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008; 359:378-90
6. Colombo M: Sorafenib in advanced hepatocellular carcinoma: a further step toward personalized therapy of liver cancer. Gastroenterology, 2009; 136:1832-5
7. Huether A, Hopfner M, Baradari V, et al: Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol, 2007; 73:1308-17
8. Verslype C, Prenen H, Van Cutsem E: The role of chemotherapy in biliary tract carcinoma. HPB (Oxford), 2008; 10:164-7
9. Anderson CD, Pinson CW, Berlin J, et al: Diagnosis and treatment of cholangiocarcinoma. Oncologist, 2004 9:43-57
10. Takada T, Kato H, Matsushiro T, et al: Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology, 1994;51:396-400
11. Choi CW, Choi IK, Seo JH, et al: Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol, 2000; 23:425-8
12. Patt YZ, Jones DV, Jr., Hoque A, et al: Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol, 1996; 14:2311-5
13. Patt YZ, Hassan MM, Lozano RD, et al: Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res, 2001; 7:3375-80
14. Ducreux M, Rougier P, Fandi A, et al: Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol, 1998; 9:653-6
15. Lee MA, Woo IS, Kang JH, et al: Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol, 2004; 130:346-50
16. Taieb J, Mitry E, Boige V, et al: Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol, 2002; 13:1192-6
17. Raderer M, Hejna MH, Valencak JB, et al: Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology, 1999; 56:177-80
18. Jones DV, Jr., Lozano R, Hoque A, et al: Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol, 1996; 14:2306-10
19. Kiba T, Nishimura T, Matsumoto S, et al: Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology, 2006; 70:358-65
20. Scheithauer W: Review of gemcitabine in biliary tract carcinoma. Semin Oncol, 2002; 29:40-5
21. Okaro AC, Deery AR, Hutchins RR, et al: The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol, 2001; 54:927-32
22. Craig RW: MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia, 2002; 16:444-54
23. Taniai M, Grambihler A, Higuchi H, et al: Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res, 2004; 64:3517-24
24. Kobayashi S, Werneburg NW, Bronk SF, et al: Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology, 2005; 128:2054-65
25. Kim SH, Ricci MS, El-Deiry WS: Mcl-1: a gateway to TRAIL sensitization. Cancer Res, 2008 68:2062-4
26. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 2006; 66:11851-8
27. Yu C, Bruzek LM, Meng XW, et al: The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene, 2005; 24:6861-9
28. Ogasawara S, Yano H, Higaki K, et al: Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol Res, 2001; 20:97-113